New hope for muscle disease: experimental drug ARO-DM1 enters human trials
NCT ID NCT06138743
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called ARO-DM1 in 78 adults aged 18-65 with type 1 myotonic dystrophy, a genetic muscle disorder. The goal is to check safety and how the body processes the drug. Participants receive either ARO-DM1 or a placebo by IV or injection. It is an early-stage trial, so results will guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ARO-DM1
- What this could lead to
- If successful, this could lead to a treatment that controls symptoms of myotonic dystrophy type 1, improving muscle function and quality of life.
- What could go wrong
- This is an early-phase trial (Phase 1/2a) with only 78 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGLiverpool, New South Wales, 2170, Australia
-
Research Site
RECRUITINGBirtinya, Queensland, 4575, Australia
-
Research Site
RECRUITINGHerston, Queensland, 4029, Australia
-
Research Site
RECRUITINGMelbourne, Victoria, 3004, Australia
-
Research Site
RECRUITINGChristchurch, 8011, New Zealand
-
Research Site
RECRUITINGTaichung, 40447, Taiwan
-
Research Site
RECRUITINGTaipei, 10041, Taiwan
-
Research Site
RECRUITINGTaipei, 11217, Taiwan
-
Research Site
RECRUITINGBangkok, Bangkok, 10700, Thailand
-
Research Site
RECRUITINGHat Yai, Changwat Songkhla, 90110, Thailand
-
Research Site
RECRUITINGLampang, 52000, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists hunt for biomarkers to unlock DM1 treatments
- 700-Patient study seeks key clues to muscle disease
- Brain scans reveal diabetes link to cognitive decline in rare disease
- New drug AOC 1001 tested for rare muscle disease
- Spanish researchers launch massive DM1 registry to unlock disease secrets
- New hope for muscle stiffness: experimental drug ATX-01 enters human trials